News Trump blocks plan for Medicare to cover weight-loss drugs A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.
News ACC25: Ozempic shows its value in PAD Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.
Market Access UK weight loss market: M&A opportunities Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities
News Novo Nordisk looks east for another obesity therapy Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.
News Novo Nordisk returns to ABPI fold after two-year suspension Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."
News Novo Nordisk's CagriSema data disappoints investors again Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.
News Enhertu poised to move first line in HER2+ breast cancer New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
